News and Events

Ampersand Capital Partners Acquires Pacific Biomarkers and Merges Company with NEOMED-LABS

November 19, 2018

WELLESLEY, MA, LAVAL, QC, and SEATTLE, WA, November 19, 2018 – Ampersand Capital Partners announced today that it has completed the acquisition of Pacific Biomarkers and merged it with existing portfolio company NEOMED-LABS. This merger brings together two leading bioanalytical CROs with unrivaled credentials in immunology and particular expertise in assay development, custom biomarker validation, … Continued

Ampersand Invests in Management Buyout of Clinical Immunology Provider NEOMED-LABS from the NEOMED Institute

September 4, 2018

LAVAL, QC. and WELLESLEY, MA., September 4, 2018 – Ampersand Capital Partners, together with the management team of NEOMED-LABS and the NEOMED Institute, announced today that Ampersand has partnered with management in the acquisition of NEOMED-LABS from its not-for-profit founder and parent, the NEOMED Institute. NEOMED-LABS is a leading provider of clinical immunology laboratory services … Continued

NEOMED-LABS Renews Strategic Agreement with GSK

May 31, 2018

Laval, May 31, 2018 – Laval headquartered NEOMED-LABS, a global leader in the clinical immunology field, announces today a 3-year extension of their strategic agreement with GSK, the world’s largest vaccine manufacturer. Under the terms of this renewed agreement, NEOMED-LABS will develop immunotools (antigens), immunochemical assays as well as functional assays and undertake the clinical … Continued

NEOMED-LABS awarded GCLP Accreditation

March 30, 2017

Montreal, March 30, 2017 – NEOMED-LABS, a Canadian specialty company providing customized and high-throughput immune-monitoring for clinical vaccine and biologics development, announced today that their laboratories have been granted the Good Clinical Laboratory Practices (GCLP) Accreditation by Qualogy Ltd.   “This is an important milestone for our growing organization to be provided an independent assessment … Continued